Logotype for Absci Corporation

Absci (ABSI) investor relations material

Absci Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Absci Corporation
Q3 2026 earnings summary12 Nov, 2026

Executive summary

  • ABS-201 HEADLINE is progressing in Phase 1/2a for pattern hair loss; interim 13-week proof-of-concept data are expected in December 2026 and full 26-week data in early 2027.

  • A Phase 2 STORYLINE trial for endometriosis is planned for mid-2027; ABS-202 remains in nonclinical development.

  • Origin-1 generative design paired with lab-in-the-loop validation; the first two programs reached IND or foreign equivalent in ~2 years at ~$15M per program, versus cited industry averages of 4–6 years and >$50M.

Financial highlights

  • Q3 partner program revenue was $0.304M vs. $0.378M YoY; net loss was $33.3M vs. $28.7M.

  • Q3 R&D expense was $23.6M vs. $19.2M, mainly reflecting ABS-201 development; SG&A was $9.0M vs. $8.4M, primarily due to stock-based compensation.

  • 9M revenue was $0.837M vs. $2.150M and net loss was $96.1M vs. $85.6M.

  • 9M R&D expense rose 17% to $65.5M; operating expenses increased 10% to $100.8M, including SG&A of $27.3M and D&A of $8.1M.

  • Q3 diluted loss per share was $0.19 vs. $0.20; 9M diluted loss per share was $0.60 vs. $0.65.

Outlook and guidance

  • Interim 13-week HEADLINE data are expected in December 2026, including all 300 mg participants, most 600 mg participants and potentially an initial look at 1,200 mg; full 26-week data are expected in early 2027.

  • The 26-week results will inform Phase 3 dose selection; the 13-week interim is directional and not intended to change trial conduct.

  • STORYLINE is planned for mid-2027, subject to protocol finalization and regulatory clearance; planned enrollment is ~150 patients across ~10 or more countries.

  • Cash, cash equivalents and marketable securities of $173.7M are projected to fund operating plans into H2 2028.

  • R&D expense is expected to rise as HEADLINE, later-stage PHL trials, STORYLINE, other internal programs and platform investment advance.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Absci earnings date

Logotype for Absci Corporation
Jefferies Global Healthcare Conference18 Nov, 2026
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Absci earnings date

Logotype for Absci Corporation
Jefferies Global Healthcare Conference18 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Absci Corporation operates as a generative AI drug creation company, focusing on revolutionizing the process of biologics drug discovery. Leveraging an integrated drug creation platform, Absci identifies novel drug targets and creates biotherapeutic candidates, shifting from traditional drug discovery to drug creation. This approach enables the design of de novo antibodies directly on computers, potentially reducing the development time for new drug leads and increasing their probability of success. The company's platform combines artificial intelligence with synthetic biology, allowing the construction and testing of millions of AI designs weekly. This innovative process results in wet lab-validated biologic-based therapeutics in a significantly shortened timeframe, aiming to address the challenges of traditionally high failure rates and lengthy development times in biologics drug discovery. The company is headquartered in Vancouver, Washington, and its shares are listed on the Nasdaq.